Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own1.10% Shs Outstand164.62M Perf Week1.70%
Market Cap17.83B Forward P/E- EPS next Y-0.78 Insider Trans-12.57% Shs Float164.62M Perf Month31.11%
Income-304.30M PEG- EPS next Q-0.47 Inst Own- Short Float4.22% Perf Quarter37.51%
Sales801.40M P/S22.25 EPS this Y-61.10% Inst Trans1.83% Short Ratio7.38 Perf Half Y69.32%
Book/sh10.59 P/B10.23 EPS next Y51.20% ROA-18.00% Target Price110.13 Perf Year78.83%
Cash/sh5.29 P/C20.49 EPS next 5Y23.00% ROE-21.60% 52W Range51.50 - 108.95 Perf YTD91.14%
Dividend- P/FCF- EPS past 5Y-22.40% ROI-18.60% 52W High1.78% Beta2.00
Dividend %- Quick Ratio4.50 Sales past 5Y19.40% Gross Margin91.60% 52W Low115.32% ATR3.38
Employees1302 Current Ratio4.90 Sales Q/Q25.90% Oper. Margin-34.00% RSI (14)75.63 Volatility3.19% 3.34%
OptionableYes Debt/Eq0.00 EPS Q/Q-29.10% Profit Margin-38.00% Rel Volume1.05 Prev Close108.30
ShortableYes LT Debt/Eq0.00 EarningsOct 29 AMC Payout- Avg Volume940.10K Price110.89
Recom2.10 SMA2010.12% SMA5029.04% SMA20047.27% Volume621,649 Change2.39%
Oct-22-19Reiterated H.C. Wainwright Buy $98 → $140
Oct-22-19Reiterated BofA/Merrill Underperform $58 → $83
Sep-27-19Upgrade Goldman Neutral → Buy $78 → $100
Aug-26-19Initiated BTIG Research Neutral
Jul-18-19Initiated Deutsche Bank Hold $79
Jul-17-19Upgrade Piper Jaffray Neutral → Overweight $64 → $75
Apr-11-19Initiated Stifel Hold $70
Mar-27-19Initiated Berenberg Buy $95
Oct-26-18Reiterated Barclays Overweight $95 → $90
Oct-26-18Downgrade BofA/Merrill Neutral → Underperform
Sep-25-18Initiated Leerink Partners Outperform
Sep-07-18Resumed Piper Jaffray Neutral
Jul-30-18Reiterated Needham Buy $74 → $79
Jul-27-18Reiterated H.C. Wainwright Buy $77 → $98
Jun-11-18Upgrade SunTrust Hold → Buy
Mar-20-18Resumed Barclays Overweight $74
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Feb-07-18Reiterated Needham Buy $72 → $74
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Nov-07-19 08:00AM  Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting Business Wire
Nov-05-19 08:00AM  Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate Business Wire
06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga
Nov-04-19 11:51PM  Seattle Genetics Responds to Daiichi Sankyos Complaint for Declaratory Judgment Business Wire
08:00AM  Seattle Genetics to Present at Credit Suisse 28th Annual Healthcare Conference Business Wire
Nov-01-19 10:03AM  Baker Brothers Make $1.4 Billion in Two Weeks on Biotech Bloomberg
07:36AM  Edited Transcript of SGEN earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-30-19 12:29PM  Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark Zacks
Oct-29-19 05:25PM  Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:02PM  Seattle Genetics Reports Third Quarter 2019 Financial Results Business Wire
Oct-27-19 12:56PM  The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings Benzinga
Oct-23-19 09:45AM  Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates Zacks
Oct-22-19 10:06AM  Seattle Genetics: Where's This Biotech Stock Headed From Here? TheStreet.com
Oct-21-19 04:15PM  This Biotech Stock Piggybacked On Roche's Blockbuster And Succeeded Investor's Business Daily +15.43%
03:20PM  Seattle Genetics Options Volume Skyrockets as Shares Soar Schaeffer's Investment Research
12:59PM  Dow Jones Lags, Boeing Bombarded Again; These Growth Stocks Are Emerging As New Leaders Investor's Business Daily
12:42PM  Baker Brothers Makes $730 Million in One Day on Its Biotech Bet Bloomberg
10:01AM  Here's Why We're Not At All Concerned With Seattle Genetics's (NASDAQ:SGEN) Cash Burn Situation Simply Wall St.
09:58AM  Seattle Genetics stock soars 15% on positive trial of breast cancer treatment MarketWatch
09:36AM  Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study Benzinga
07:04AM  Seattle Genetics Shares Rise On Positive Results From Breast Cancer Drug Trial TheStreet.com
06:45AM  Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Oct-16-19 03:23PM  Four stocks that are nearing key breakouts MarketWatch
11:51AM  4 Stocks Nearing Key Breakouts Benzinga
Oct-12-19 02:16PM  Did Hedge Funds Drop The Ball On Seattle Genetics, Inc. (SGEN) ? Insider Monkey
Oct-11-19 12:40PM  Seattle Genetics Begins Phase III Study on Tucatinib Combo Zacks
Oct-10-19 11:15AM  Seattle Genetics Up More Than 20% in 3 Months: Here's Why Zacks
08:00AM  Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Oct-08-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019 Business Wire
Oct-06-19 07:55AM  Goldman Sachs: 3 Stocks to Buy Despite Recession Fears TipRanks
Oct-01-19 04:42PM  Immunomedics (IMMU) Reports Interim Urothelial Cancer Data Zacks
12:58PM  A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019 Benzinga
11:45AM  Seattle Genetics Up on Positive Data From Bladder Cancer Study Zacks
09:42AM  Company News For Oct 1, 2019 Zacks
Sep-30-19 04:31PM  Why This Biotech Stock Just Broke Out In Bullish Volume And Another Toppled Investor's Business Daily +12.37%
02:07PM  Seattle Genetics, Merck, Bristol-Myers Unveil Upbeat Treatment Data at Cancer Conference Barrons.com
01:13PM  Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More Benzinga
12:05PM  A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019 Benzinga
09:15AM  Seattle Genetics Climbs on Positive Trial Results for Bladder Cancer Treatment TheStreet.com
08:33AM  Immunomedics Stock Drops After Bladder-Cancer-Drug Results Disappoint TheStreet.com
Sep-29-19 03:01PM  The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear Benzinga
09:00AM  Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer Business Wire
Sep-28-19 02:30AM  Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer Business Wire
Sep-27-19 05:22PM  This Biotech Stock Is Nearing A Breakout On Its Cancer Test Touchdown Investor's Business Daily
Sep-20-19 02:22PM  The Seattle Genetics (NASDAQ:SGEN) Share Price Has Gained 76% And Shareholders Are Hoping For More Simply Wall St.
Sep-17-19 10:44AM  Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review Zacks
08:00AM  Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress Business Wire
Sep-16-19 08:00AM  Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Sep-12-19 12:51PM  Oppenheimer Turns Bullish On Seattle Genetics, Says Optimism Fueled By Pipeline Readouts Benzinga
Sep-10-19 09:15PM  Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.9 million of Shares GuruFocus.com
Sep-08-19 11:01AM  The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight Benzinga
Aug-30-19 06:15PM  Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $2.1 million of Shares GuruFocus.com
Aug-23-19 05:18PM  Therapeutics startup raises $65M in latest round to fight kidney disease American City Business Journals
Aug-22-19 07:15PM  Seattle Genetics Inc (SGEN) CFO Todd E Simpson Sold $1,000,000 of Shares GuruFocus.com
Aug-19-19 09:11AM  Did Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Sell Shares? Simply Wall St.
Aug-15-19 08:12PM  Alder on hiring binge ahead of FDA ruling American City Business Journals
09:30AM  Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report? Zacks
Aug-09-19 08:15PM  Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.5 million of Shares GuruFocus.com
Aug-03-19 01:15AM  Top Biotech Stocks for February 2019 Investopedia
Jul-26-19 11:49AM  Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares Business Wire
Jul-23-19 10:26PM  Seattle Genetics Announces Pricing of Public Offering of Common Stock Business Wire
04:09PM  Seattle Genetics Announces Proposed Public Offering of Common Stock Business Wire
07:41AM  Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More Benzinga
07:31AM  Seattle Genetics Has a Rally in Its DNA TheStreet.com
03:03AM  3 Perfect 10 Biotech Stocks to Buy TipRanks
Jul-18-19 05:07PM  Edited Transcript of SGEN earnings conference call or presentation 16-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
02:41PM  Seattle Genetics Hits Its Second Growth Phase Motley Fool
Jul-17-19 04:26PM  Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today Motley Fool +18.98%
12:20PM  Here's Why Seattle Genetics Rocketed Higher Today Motley Fool
10:58AM  Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks
01:23AM  Seattle Genetics Inc (SGEN) Q2 2019 Earnings Call Transcript Motley Fool
Jul-16-19 05:25PM  Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:13PM  The Surprising Reason This Biotech Stock Got An After-Hours Boost Investor's Business Daily
04:02PM  Seattle Genetics Reports Second Quarter 2019 Financial Results Business Wire
02:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM  Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Jul-13-19 05:04PM  The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings Benzinga
08:01AM  Brief Commentary On Seattle Genetics, Inc.'s (NASDAQ:SGEN) Fundamentals Simply Wall St.
Jul-10-19 08:15PM  Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.3 million of Shares GuruFocus.com -5.21%
Jul-09-19 10:30AM  Earnings Preview: Seattle Genetics (SGEN) Q2 Earnings Expected to Decline Zacks
Jul-02-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019 Business Wire
Jun-24-19 09:00AM  Natasha A. Hernday Elected to PDL BioPharma's Board of Directors PR Newswire
Jun-20-19 07:16PM  Clay Siegall continues Seattle Genetics' fast expansion, growth American City Business Journals
Jun-19-19 06:00PM  Heres What Hedge Funds Think About Seattle Genetics, Inc. (SGEN) Insider Monkey
Jun-18-19 08:03AM  Roche's Rozlytrek Gets Approval in Japan for Solid Tumors Zacks
Jun-17-19 09:51AM  Does Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Salary Compare Well With Others? Simply Wall St.
Jun-12-19 08:00AM  Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML) Business Wire
Jun-11-19 09:54AM  Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II Zacks
Jun-10-19 12:51PM  Seattle Genetics Antibody-Drug Conjugate Technology Utilized in Genentechs Polivy, Now Approved by FDA Business Wire
Jun-04-19 05:30PM  Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR Zacks
Jun-03-19 04:24PM  Who Are The Winners And Losers From The Year's Biggest Cancer Meeting? Investor's Business Daily
11:22AM  Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study Reuters
09:22AM  Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study Reuters
08:00AM  Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting Business Wire
07:30AM  Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer Business Wire
07:30AM  Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer PR Newswire
Jun-01-19 11:37AM  The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga
May-29-19 08:36PM  Revealed: PSBJ inaugural Middle Market Fast 50 list makers American City Business Journals
May-25-19 09:31AM  Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound? Zacks
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.0028,472341,664770,104Oct 10 06:55 PM
SIEGALL CLAY BPresident and CEOOct 08Sale82.4728,4722,348,061755,684Oct 10 06:55 PM
GRYSKA DAVID WDirectorOct 01Option Exercise15.895,00079,45050,513Oct 03 07:38 PM
GRYSKA DAVID WDirectorOct 01Sale85.095,000425,45048,013Oct 03 07:38 PM
SIMPSON TODD EChief Financial OfficerSep 30Sale85.0015,0001,275,000157,567Oct 02 06:12 PM
LIU JEAN IGC/EVP, Leg AffairsSep 30Sale86.007,432639,15270,688Oct 02 06:10 PM
DANSEY ROGER DChief Medical OfficerSep 25Sale73.803,000221,415103,146Sep 27 06:12 PM
SIEGALL CLAY BPresident and CEOSep 09Option Exercise12.0028,472341,664774,374Sep 10 07:29 PM
SIEGALL CLAY BPresident and CEOSep 09Sale68.3328,4721,945,531755,684Sep 10 07:29 PM
SIEGALL CLAY BSee RemarksSep 03Sale70.809,693686,257755,684Sep 04 09:46 PM
DANSEY ROGER DSee RemarksSep 03Sale70.8092265,277106,146Sep 04 09:43 PM
SIMPSON TODD ESee RemarksSep 03Sale70.802,092148,112172,567Sep 04 09:42 PM
HIMES VAUGHN BSee RemarksSep 03Sale70.805,692402,990187,518Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Option Exercise12.008,00096,000201,210Sep 04 09:45 PM
HIMES VAUGHN BSee RemarksAug 30Sale72.868,000582,859193,210Sep 04 09:45 PM
LIU JEAN IGC/EVP, Leg AffairsAug 28Sale73.226,013440,24260,904Aug 30 04:35 PM
SIEGALL CLAY BPresident and CEOAug 28Sale73.2128,9512,119,636717,343Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 28Sale73.215,909432,624153,371Aug 30 04:36 PM
HIMES VAUGHN BChief Technical OfficerAug 28Sale73.216,836500,496175,197Aug 30 04:35 PM
SIMPSON TODD EChief Financial OfficerAug 20Sale80.0012,5001,000,000159,280Aug 22 05:49 PM
LIU JEAN IGC/EVP, Leg AffairsAug 20Sale80.003,716297,28066,917Aug 22 05:47 PM
SIEGALL CLAY BPresident and CEOAug 08Option Exercise12.1620,149245,012756,192Aug 09 05:06 PM
SIEGALL CLAY BPresident and CEOAug 08Sale76.5220,1491,541,827746,294Aug 09 05:06 PM
LIU JEAN IGC/EVP, Leg AffairsAug 06Sale75.003,716278,70070,633Aug 08 05:42 PM
GRYSKA DAVID WDirectorJul 17Option Exercise12.765,00063,80053,013Jul 19 06:20 PM
GRYSKA DAVID WDirectorJul 17Sale75.005,000375,00048,013Jul 19 06:20 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.1620,148245,000761,011Jul 10 06:57 PM
SIEGALL CLAY BPresident and CEOJul 08Sale66.8920,1481,347,664746,294Jul 10 06:57 PM
HIMES VAUGHN BChief Technical OfficerJun 24Option Exercise42.514,704199,970182,033Jun 26 06:26 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale68.605,416371,53877,593Jun 19 06:43 PM
SIEGALL CLAY BPresident and CEOJun 10Option Exercise12.1620,148245,000760,119Jun 12 05:51 PM
SIEGALL CLAY BPresident and CEOJun 10Sale69.0520,1481,391,175749,169Jun 12 05:51 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.008,00096,000185,329Jun 04 06:28 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale65.948,000527,485177,329Jun 04 06:28 PM
SIEGALL CLAY BPresident and CEOMay 09Option Exercise12.164,82458,660752,063May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 09Sale67.434,824325,301749,169May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.1615,324186,340762,600May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Sale68.2615,3241,046,066749,169May 10 04:39 PM
BAKER BROS. ADVISORS LPDirectorApr 29Option Exercise8.3820,000167,60045,839,686May 01 04:59 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.1620,148245,000757,976Apr 10 04:39 PM
SIEGALL CLAY BPresident and CEOApr 08Sale79.2220,1481,596,100749,169Apr 10 04:39 PM
SIMPSON TODD EChief Financial OfficerApr 05Sale78.0012,500975,000171,780Apr 09 08:35 PM
GRYSKA DAVID WDirectorApr 01Option Exercise12.765,00063,80050,050Apr 03 08:57 PM
GRYSKA DAVID WDirectorApr 01Sale73.415,000367,03045,050Apr 03 08:57 PM
SIEGALL CLAY BPresident and CEOMar 18Option Exercise12.0816,556199,988749,169Mar 20 06:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Option Exercise12.008,00096,000185,329Mar 12 07:31 PM
SIEGALL CLAY BPresident and CEOMar 08Option Exercise12.1620,148245,000745,259Mar 12 07:34 PM
SIEGALL CLAY BPresident and CEOMar 08Sale69.1920,1481,394,094732,613Mar 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Sale68.728,000549,746177,329Mar 12 07:31 PM
SIMPSON TODD EChief Financial OfficerMar 04Sale75.0010,000750,000184,280Mar 06 06:58 PM
SIEGALL CLAY BSee RemarksFeb 08Option Exercise12.1620,148245,000740,690Feb 12 06:25 PM
SIEGALL CLAY BSee RemarksFeb 08Sale65.1720,1481,313,126732,613Feb 12 06:25 PM
GRYSKA DAVID WDirectorJan 08Option Exercise12.765,00063,80050,050Jan 10 09:09 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.1620,148245,000739,713Jan 10 08:27 PM
SIEGALL CLAY BPresident and CEOJan 08Sale65.7320,1481,324,237732,613Jan 10 08:27 PM
GRYSKA DAVID WDirectorJan 08Sale65.045,000325,20045,050Jan 10 09:09 PM
SIEGALL CLAY BPresident and CEODec 10Option Exercise12.1620,148245,000745,761Dec 12 07:31 PM
SIEGALL CLAY BPresident and CEODec 10Sale59.7420,1481,203,545732,613Dec 12 07:31 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.005,00060,000177,329Dec 04 07:37 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale62.145,000310,718172,329Dec 04 07:37 PM
Cline Darren SEVP, CommercialNov 29Sale62.887,000440,16072,556Nov 30 06:32 PM
Cline Darren SEVP, CommercialNov 21Sale56.684,167236,20479,556Nov 21 06:42 PM